M. Liset Rietman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
M. Liset Rietman has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- W. M. Monique Verschuren
National Institute for Public Health and the Environment, Bilthoven, The Netherlands
4 shared publications H. Susan J. Picavet
Center for Prevention, Lifestyle and Health, Dutch National Institute for Public Health and the Environment, 3721, Bilthoven, The Netherlands
3 shared publicationsW. M. Monique Verschuren
National Institute for Public Health and the Environment, Bilthoven, The Netherlands
3 shared publicationsAlbert Wong
National Institute for Public Health and the Environment, Bilthoven, The Netherlands
2 shared publicationsAnnemieke M. W. Spijkerman
National Institute for Public Health and the Environment, Bilthoven, The Netherlands
2 shared publicationsAstrid C. J. Nooyens
National Institute for Public Health and the Environment, Bilthoven, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (10) , 5889-5899
Genetics of major depressive disorder in a homogeneous population with uniform phenotyping
Harmonized phenotyping and diverse population-specific studies are crucial for advancing gene discovery in psychiatric genetics. We conducted a genome-wide association (GWAS) mega-analysis of DSM-defined lifetime major depressive disorder (MDD) in 64 941 participants (25.7% cases) from the Dutch BIObanks Netherlands Internet Collaboration (BIONIC) consortium. Liability-scale SNP-based heritability was 12.0% (SE = 1.4%) as estimated by LDSC (assuming a lifetime prevalence of 15%) and 26.6% (SE = 1.1%) when estimated by LDAK-REML on individual-level genotype data, indicating substantial common-variant signal in this clinically harmonized sample. The genetic correlation with the latest major depression GWAS from the Psychiatric Genomics Consortium (PGC-MD) was high (rG = 0.89, SE = 0.048). Polygenic scores (PGSs) based on BIONIC predicted depression in UK Biobank, and PGSs derived from PGC-MD predicted MDD in BIONIC, supporting transferability of depression polygenic signal across cohorts and phenotype definitions. Within-family PGS analyses in twins suggested that the observed prediction was not primarily driven by detectable family-level confounding, and twin concordance for MDD increased with polygenic burden. We identified one genome-wide significant locus, indexed by rs3818852 in PALMD, but this finding currently lacks independent replication and should be interpreted cautiously. Finally, genetic correlation and latent causal variable analyses identified multiple traits showing shared or directionally consistent genetic associations with MDD. Together, these findings underscore the value of clinically harmonized phenotyping in regional biobank collaborations for studying the genetic architecture of MDD.
- 2 June 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (10) , 5889-5899
Open AccessGenetics of major depressive disorder in a homogeneous population with uniform phenotyping
Harmonized phenotyping and diverse population-specific studies are crucial for advancing gene discovery in psychiatric genetics. We conducted a genome-wide association (GWAS) mega-analysis of DSM-defined lifetime major depressive disorder (MDD) in 64 941 participants (25.7% cases) from the Dutch BIObanks Netherlands Internet Collaboration (BIONIC) consortium. Liability-scale SNP-based heritability was 12.0% (SE = 1.4%) as estimated by LDSC (assuming a lifetime prevalence of 15%) and 26.6% (SE = 1.1%) when estimated by LDAK-REML on individual-level genotype data, indicating substantial common-variant signal in this clinically harmonized sample. The genetic correlation with the latest major depression GWAS from the Psychiatric Genomics Consortium (PGC-MD) was high (rG = 0.89, SE = 0.048). Polygenic scores (PGSs) based on BIONIC predicted depression in UK Biobank, and PGSs derived from PGC-MD predicted MDD in BIONIC, supporting transferability of depression polygenic signal across cohorts and phenotype definitions. Within-family PGS analyses in twins suggested that the observed prediction was not primarily driven by detectable family-level confounding, and twin concordance for MDD increased with polygenic burden. We identified one genome-wide significant locus, indexed by rs3818852 in PALMD, but this finding currently lacks independent replication and should be interpreted cautiously. Finally, genetic correlation and latent causal variable analyses identified multiple traits showing shared or directionally consistent genetic associations with MDD. Together, these findings underscore the value of clinically harmonized phenotyping in regional biobank collaborations for studying the genetic architecture of MDD.
- Open Access
- 17 March 2026
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (5) , 1150-1157
Association of body mass index, waist circumference, (abdominal) overweight and obesity with sex- and age-specific cognitive function over time—the Doetinchem Cohort Study
Background Having obesity is a risk factor for cognitive decline and dementia. It remains unclear whether timing of obesity during someone’s lifespan affects this association. Aim To study the association of body mass index (BMI), waist circumference (WC), and having (abdominal) overweight and obesity with cognitive function and decline, and whether these associations were modified by age. Methods 3873 participants (aged 45–70 at baseline, 52% women) from the Doetinchem Cohort Study were included, with up to six repeated measures. Participants were classified as having (abdominal) obesity if they had a BMI ≥30 kg/m² or WC ≥102 cm (men) or ≥88 cm (women). Domain scores for global cognition, memory, flexibility, and processing speed were calculated by standardizing individual test scores at baseline. Associations of time-dependent BMI, WC, and (abdominal) overweight and obesity with cognitive function and decline were studied using linear mixed models. Models were sex-stratified and adjusted for socio-demographic, lifestyle, and mental health factors. Modification by age (≤ or >55 years at baseline) was evaluated using interaction terms. Results Higher BMI and WC were associated with worse level of cognition (all domains). For both sexes, the smallest difference was for global cognition (BMI) and processing speed (WC), the largest for flexibility (BMI) and memory (WC). Furthermore, having (abdominal) obesity, compared to a healthy BMI/WC, was consistently associated with worse memory function in both sexes. Effect sizes were generally larger for categorical WC compared to categorical BMI. In men, abdominal obesity was associated with accelerated decline in processing speed (all ages), and with accelerated decline in global cognition and flexibility ( > 55 years). Conclusions In both sexes, higher BMI and WC were consistently associated with worse cognition. WC-based overweight and obesity showed larger effect sizes with cognition than BMI-based overweight and obesity. Only in men, associations with cognitive decline and effect modification by age were observed.
- 17 March 2026
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (5) , 1150-1157
Open AccessAssociation of body mass index, waist circumference, (abdominal) overweight and obesity with sex- and age-specific cognitive function over time—the Doetinchem Cohort Study
Background Having obesity is a risk factor for cognitive decline and dementia. It remains unclear whether timing of obesity during someone’s lifespan affects this association. Aim To study the association of body mass index (BMI), waist circumference (WC), and having (abdominal) overweight and obesity with cognitive function and decline, and whether these associations were modified by age. Methods 3873 participants (aged 45–70 at baseline, 52% women) from the Doetinchem Cohort Study were included, with up to six repeated measures. Participants were classified as having (abdominal) obesity if they had a BMI ≥30 kg/m² or WC ≥102 cm (men) or ≥88 cm (women). Domain scores for global cognition, memory, flexibility, and processing speed were calculated by standardizing individual test scores at baseline. Associations of time-dependent BMI, WC, and (abdominal) overweight and obesity with cognitive function and decline were studied using linear mixed models. Models were sex-stratified and adjusted for socio-demographic, lifestyle, and mental health factors. Modification by age (≤ or >55 years at baseline) was evaluated using interaction terms. Results Higher BMI and WC were associated with worse level of cognition (all domains). For both sexes, the smallest difference was for global cognition (BMI) and processing speed (WC), the largest for flexibility (BMI) and memory (WC). Furthermore, having (abdominal) obesity, compared to a healthy BMI/WC, was consistently associated with worse memory function in both sexes. Effect sizes were generally larger for categorical WC compared to categorical BMI. In men, abdominal obesity was associated with accelerated decline in processing speed (all ages), and with accelerated decline in global cognition and flexibility ( > 55 years). Conclusions In both sexes, higher BMI and WC were consistently associated with worse cognition. WC-based overweight and obesity showed larger effect sizes with cognition than BMI-based overweight and obesity. Only in men, associations with cognitive decline and effect modification by age were observed.
- Open Access
- 11 August 2025
- Published by Springer Nature in European Journal of Ageing
- Vol. 22 (1) , 42
Individual vitality changes over 20 years among aging adults, using predefined and data-driven patterns: the Doetinchem Cohort Study
'Vitality' refers to healthy aging beyond medical measures, but long-term data on vitality is scarce. Hence, we examined individual vitality patterns over 20 years, and their lifestyle and health characteristics, using predefined and data-driven methods. We used data of 3,013 adults aged 26-70 at their first vitality measurement from the Doetinchem Cohort Study examined up to 5 times from 1995 to 2019 at 5-year intervals. Vitality was based on the SF-36 vitality scale, with scores > 50 indicating good vitality. Long-term vitality patterns were defined by two approaches, predefined and data-driven, and compared using cross-tabulation and Cramér's V. The predefined patterns were: persistent good, persistent poor, worsening, improving, and varying vitality. The lifestyle and health characteristics related to these patterns were identified by multivariate multinomial logistic regression, using persistent good vitality as the reference at both baseline (t1) and 20-year follow-up (t5). Data-driven analysis revealed patterns similar to the predefined method with varying vitality split in two variants. There was fair agreement between the approaches (Cramér's V: 0.49). Most participants exhibited persistent good vitality: 61% in the predefined, and 78% in the data-driven approach. Compared to the persistent good vitality group, others were characterized by younger age and poor health, including pain, chronic conditions, and particularly high prevalence of poor mental health. Sex, education, household and work status, along with lifestyle factors, played a role in only some patterns. Most adults showed persistent good vitality over 20 years, with good mental health as a key characteristic of long-term vitality.
- 11 August 2025
- Published by Springer Nature in European Journal of Ageing
- Vol. 22 (1) , 42
Open AccessIndividual vitality changes over 20 years among aging adults, using predefined and data-driven patterns: the Doetinchem Cohort Study
'Vitality' refers to healthy aging beyond medical measures, but long-term data on vitality is scarce. Hence, we examined individual vitality patterns over 20 years, and their lifestyle and health characteristics, using predefined and data-driven methods. We used data of 3,013 adults aged 26-70 at their first vitality measurement from the Doetinchem Cohort Study examined up to 5 times from 1995 to 2019 at 5-year intervals. Vitality was based on the SF-36 vitality scale, with scores > 50 indicating good vitality. Long-term vitality patterns were defined by two approaches, predefined and data-driven, and compared using cross-tabulation and Cramér's V. The predefined patterns were: persistent good, persistent poor, worsening, improving, and varying vitality. The lifestyle and health characteristics related to these patterns were identified by multivariate multinomial logistic regression, using persistent good vitality as the reference at both baseline (t1) and 20-year follow-up (t5). Data-driven analysis revealed patterns similar to the predefined method with varying vitality split in two variants. There was fair agreement between the approaches (Cramér's V: 0.49). Most participants exhibited persistent good vitality: 61% in the predefined, and 78% in the data-driven approach. Compared to the persistent good vitality group, others were characterized by younger age and poor health, including pain, chronic conditions, and particularly high prevalence of poor mental health. Sex, education, household and work status, along with lifestyle factors, played a role in only some patterns. Most adults showed persistent good vitality over 20 years, with good mental health as a key characteristic of long-term vitality.
- Open Access
- 4 November 2024
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 53 (11)
Association between metabolomics-based biomarker scores and 10-year cognitive decline in men and women. The Doetinchem Cohort Study
Metabolomic scores based on age (MetaboAge) and mortality (MetaboHealth) are considered indicators of overall health, but their association with cognition in the general population is unknown. Therefore, the association between MetaboAge/MetaboHealth and level and decline in cognition was studied, as were differences between men and women. Data of 2821 participants (50% women, age range 45–75) from the Doetinchem Cohort Study was used. MetaboAge and MetaboHealth were calculated from 1H-NMR metabolomics data at baseline. Cognitive domain scores (memory, flexibility and processing speed) and global cognitive functioning were available over a 10-year period. The association between MetaboAge/MetaboHealth and level of cognitive functioning was studied using linear regressions while for the association between MetaboAge/MetaboHealth and cognitive decline longitudinal linear mixed models were used. Analyses were adjusted for demographics and lifestyle factors. Higher MetaboAge, indicating poorer metabolomic ageing, was only associated with lower levels of processing speed in men. Higher MetaboHealth, indicating poorer immune-metabolic health, was associated with lower levels of cognitive functioning for all three domains and global cognitive functioning in both men and women. Only in men, MetaboHealth was also associated with 10-year decline in flexibility, processing speed and global cognition. Metabolites that contributed to the observed associations were in men mainly markers of protein metabolism, and in women mainly markers of lipid metabolism and inflammatory metabolites. MetaboHealth, not MetaboAge, was associated with cognitive functioning independent of conventional risk factors. Individual metabolites affect cognitive functioning differently in men and women, suggesting sex-specific pathophysiological pathways underlying cognitive functioning.
- 4 November 2024
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 53 (11)
Open AccessAssociation between metabolomics-based biomarker scores and 10-year cognitive decline in men and women. The Doetinchem Cohort Study
Metabolomic scores based on age (MetaboAge) and mortality (MetaboHealth) are considered indicators of overall health, but their association with cognition in the general population is unknown. Therefore, the association between MetaboAge/MetaboHealth and level and decline in cognition was studied, as were differences between men and women. Data of 2821 participants (50% women, age range 45–75) from the Doetinchem Cohort Study was used. MetaboAge and MetaboHealth were calculated from 1H-NMR metabolomics data at baseline. Cognitive domain scores (memory, flexibility and processing speed) and global cognitive functioning were available over a 10-year period. The association between MetaboAge/MetaboHealth and level of cognitive functioning was studied using linear regressions while for the association between MetaboAge/MetaboHealth and cognitive decline longitudinal linear mixed models were used. Analyses were adjusted for demographics and lifestyle factors. Higher MetaboAge, indicating poorer metabolomic ageing, was only associated with lower levels of processing speed in men. Higher MetaboHealth, indicating poorer immune-metabolic health, was associated with lower levels of cognitive functioning for all three domains and global cognitive functioning in both men and women. Only in men, MetaboHealth was also associated with 10-year decline in flexibility, processing speed and global cognition. Metabolites that contributed to the observed associations were in men mainly markers of protein metabolism, and in women mainly markers of lipid metabolism and inflammatory metabolites. MetaboHealth, not MetaboAge, was associated with cognitive functioning independent of conventional risk factors. Individual metabolites affect cognitive functioning differently in men and women, suggesting sex-specific pathophysiological pathways underlying cognitive functioning.
- Open Access
- 10 January 2023
- Published by S. Karger AG in Gerontology
- Vol. 69 (6) , 684-693
Association of Torquetenovirus Viremia with Physical Frailty and Cognitive Impairment in Three Independent European Cohorts
Introduction: Immunosenescence and inflammaging have been implicated in the pathophysiology of frailty. Torquetenovirus (TTV), a single-stranded DNA anellovirus, the major component of the human blood virome, shows an increased replication rate with advancing age. An elevated TTV viremia has been associated with an impaired immune function and an increased risk of mortality in the older population. The objective of this study was to analyze the relation between TTV viremia, physical frailty, and cognitive impairment. Methods: TTV viremia was measured in 1,131 nonfrail, 45 physically frail, and 113 cognitively impaired older adults recruited in the MARK-AGE study (overall mean age 64.7 ± 5.9 years), and then the results were checked in two other independent cohorts from Spain and Portugal, including 126 frail, 252 prefrail, and 141 nonfrail individuals (overall mean age: 77.5 ± 8.3 years). Results: TTV viremia ≥4log was associated with physical frailty (OR: 4.69; 95% CI: 2.06–10.67, p < 0.0001) and cognitive impairment (OR: 3.49, 95% CI: 2.14–5.69, p < 0.0001) in the MARK-AGE population. The association between TTV DNA load and frailty status was confirmed in the Spanish cohort, while a slight association with cognitive impairment was observed (OR: 1.33; 95% CI: 1.000–1.773), only in the unadjusted model. No association between TTV load and frailty or cognitive impairment was found in the Portuguese sample, although a negative association between TTV viremia and MMSE score was observed in Spanish and Portuguese females. Conclusions: These findings demonstrate an association between TTV viremia and physical frailty, while the association with cognitive impairment was observed only in the younger population from the MARK-AGE study. Further research is necessary to clarify TTV’s clinical relevance in the onset and progression of frailty and cognitive decline in older individuals.
- 10 January 2023
- Published by S. Karger AG in Gerontology
- Vol. 69 (6) , 684-693
Open AccessAssociation of Torquetenovirus Viremia with Physical Frailty and Cognitive Impairment in Three Independent European Cohorts
Introduction: Immunosenescence and inflammaging have been implicated in the pathophysiology of frailty. Torquetenovirus (TTV), a single-stranded DNA anellovirus, the major component of the human blood virome, shows an increased replication rate with advancing age. An elevated TTV viremia has been associated with an impaired immune function and an increased risk of mortality in the older population. The objective of this study was to analyze the relation between TTV viremia, physical frailty, and cognitive impairment. Methods: TTV viremia was measured in 1,131 nonfrail, 45 physically frail, and 113 cognitively impaired older adults recruited in the MARK-AGE study (overall mean age 64.7 ± 5.9 years), and then the results were checked in two other independent cohorts from Spain and Portugal, including 126 frail, 252 prefrail, and 141 nonfrail individuals (overall mean age: 77.5 ± 8.3 years). Results: TTV viremia ≥4log was associated with physical frailty (OR: 4.69; 95% CI: 2.06–10.67, p < 0.0001) and cognitive impairment (OR: 3.49, 95% CI: 2.14–5.69, p < 0.0001) in the MARK-AGE population. The association between TTV DNA load and frailty status was confirmed in the Spanish cohort, while a slight association with cognitive impairment was observed (OR: 1.33; 95% CI: 1.000–1.773), only in the unadjusted model. No association between TTV load and frailty or cognitive impairment was found in the Portuguese sample, although a negative association between TTV viremia and MMSE score was observed in Spanish and Portuguese females. Conclusions: These findings demonstrate an association between TTV viremia and physical frailty, while the association with cognitive impairment was observed only in the younger population from the MARK-AGE study. Further research is necessary to clarify TTV’s clinical relevance in the onset and progression of frailty and cognitive decline in older individuals.
- Open Access
- 29 November 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-8
The APOE locus is linked to decline in general cognitive function: 20-years follow-up in the Doetinchem Cohort Study
Cognitive decline is part of the normal aging process. However, some people experience a more rapid decline than others due to environmental and genetic factors. Numerous single nucleotide polymorphisms (SNPs) have been linked to cognitive function, but only a few to cognitive decline. To understand whether cognitive function and cognitive decline are driven by the same mechanisms, we investigated whether 433 SNPs previously linked to cognitive function and 2 SNPs previously linked to cognitive decline are associated with both general cognitive functioning at baseline and general cognitive decline up to 20-years follow-up in the Doetinchem Cohort Study (DCS). The DCS is a longitudinal population-based study that enrolled men and women aged 20–59 years between 1987–1991, with follow-up examinations every 5 years. We used data of rounds 2–6 (1993–2017, n = 2559). General cognitive function was assessed using four cognition tests measuring memory, speed, fluency and flexibility. With these test scores, standardized residuals (adjusted for sex, age and examination round) were calculated for each cognition test at each round and subsequently combined into one general cognitive function measure using principal component analyses. None of the 435 previously identified variants were associated with baseline general cognitive function in the DCS. But rs429358-C, a coding apolipoprotein E (APOE) SNP and one of the variants previously associated with cognitive decline, was associated with general cognitive decline in our study as well (p-value = 1 × 10−5, Beta = −0.013). These findings suggest that decline of general cognitive function is influenced by other mechanisms than those that are involved in the regulation of general cognitive function.
- 29 November 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-8
Open AccessThe APOE locus is linked to decline in general cognitive function: 20-years follow-up in the Doetinchem Cohort Study
Cognitive decline is part of the normal aging process. However, some people experience a more rapid decline than others due to environmental and genetic factors. Numerous single nucleotide polymorphisms (SNPs) have been linked to cognitive function, but only a few to cognitive decline. To understand whether cognitive function and cognitive decline are driven by the same mechanisms, we investigated whether 433 SNPs previously linked to cognitive function and 2 SNPs previously linked to cognitive decline are associated with both general cognitive functioning at baseline and general cognitive decline up to 20-years follow-up in the Doetinchem Cohort Study (DCS). The DCS is a longitudinal population-based study that enrolled men and women aged 20–59 years between 1987–1991, with follow-up examinations every 5 years. We used data of rounds 2–6 (1993–2017, n = 2559). General cognitive function was assessed using four cognition tests measuring memory, speed, fluency and flexibility. With these test scores, standardized residuals (adjusted for sex, age and examination round) were calculated for each cognition test at each round and subsequently combined into one general cognitive function measure using principal component analyses. None of the 435 previously identified variants were associated with baseline general cognitive function in the DCS. But rs429358-C, a coding apolipoprotein E (APOE) SNP and one of the variants previously associated with cognitive decline, was associated with general cognitive decline in our study as well (p-value = 1 × 10−5, Beta = −0.013). These findings suggest that decline of general cognitive function is influenced by other mechanisms than those that are involved in the regulation of general cognitive function.
- Open Access
- 31 May 2019
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 10, 497
Trajectories of (Bio)markers During the Development of Cognitive Frailty in the Doetinchem Cohort Study
Background: Long-term changes in (bio)markers for cognitive frailty are not well characterized. Therefore, our aim is to explore (bio)marker trajectories in adults who became cognitively frail compared to age- and sex-matched controls who did not become cognitively frail over a 15 year follow-up. We hypothesize that those who become cognitively frail have more unfavorable trajectories of (bio)markers compared to controls. Methods: The Doetinchem Cohort Study is a longitudinal population-based study that started in 1987–1991 in men and women aged 20–59 years, with follow-up examinations every 5 years. For the current analyses, we used data of 17 potentially relevant (bio)markers (e.g., body mass index (BMI), urea) from rounds 2 to 5 (1993–2012). A global cognitive functioning score (based on memory, speed, and flexibility) was calculated for each round and transformed into education and examination round-adjusted z-scores. The z-score that corresponded to the 10th percentile in round 5 (z-score = −0.77) was applied as cut-off point for incident cognitive frailty in rounds 2–5. In total, 455 incident cognitively frail cases were identified retrospectively and were compared with 910 age- and sex-matched controls. Trajectories up to 15 years before and 10 years after incident cognitive frailty were analyzed using generalized estimating equations with stratification for sex and adjustment for age and, if appropriate, medication use. Results were further adjusted for level of education, depressive symptoms, BMI, and lifestyle factors. Results: In men, (bio)marker trajectories did not differ as they ran parallel and the difference in levels was not statistically significant between those who became cognitively frail compared to controls. In women, total cholesterol trajectories first increased and thereafter decreased in cognitively frail women and steadily increased in controls, gamma-glutamyltransferase trajectories were more or less stable in cognitively frail women and increased in controls, and urea trajectories increased in cognitively frail women and remained more or less stable in controls. Results were similar after additional adjustment for potential confounders. Conclusions: Out of the 17 (bio)markers included in this explorative study, differential trajectories for three biomarkers were observed in women. We do not yet consider any of the studied (bio)markers as promising biomarkers for cognitive frailty.
- 31 May 2019
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 10, 497
Open AccessTrajectories of (Bio)markers During the Development of Cognitive Frailty in the Doetinchem Cohort Study
Background: Long-term changes in (bio)markers for cognitive frailty are not well characterized. Therefore, our aim is to explore (bio)marker trajectories in adults who became cognitively frail compared to age- and sex-matched controls who did not become cognitively frail over a 15 year follow-up. We hypothesize that those who become cognitively frail have more unfavorable trajectories of (bio)markers compared to controls. Methods: The Doetinchem Cohort Study is a longitudinal population-based study that started in 1987–1991 in men and women aged 20–59 years, with follow-up examinations every 5 years. For the current analyses, we used data of 17 potentially relevant (bio)markers (e.g., body mass index (BMI), urea) from rounds 2 to 5 (1993–2012). A global cognitive functioning score (based on memory, speed, and flexibility) was calculated for each round and transformed into education and examination round-adjusted z-scores. The z-score that corresponded to the 10th percentile in round 5 (z-score = −0.77) was applied as cut-off point for incident cognitive frailty in rounds 2–5. In total, 455 incident cognitively frail cases were identified retrospectively and were compared with 910 age- and sex-matched controls. Trajectories up to 15 years before and 10 years after incident cognitive frailty were analyzed using generalized estimating equations with stratification for sex and adjustment for age and, if appropriate, medication use. Results were further adjusted for level of education, depressive symptoms, BMI, and lifestyle factors. Results: In men, (bio)marker trajectories did not differ as they ran parallel and the difference in levels was not statistically significant between those who became cognitively frail compared to controls. In women, total cholesterol trajectories first increased and thereafter decreased in cognitively frail women and steadily increased in controls, gamma-glutamyltransferase trajectories were more or less stable in cognitively frail women and increased in controls, and urea trajectories increased in cognitively frail women and remained more or less stable in controls. Results were similar after additional adjustment for potential confounders. Conclusions: Out of the 17 (bio)markers included in this explorative study, differential trajectories for three biomarkers were observed in women. We do not yet consider any of the studied (bio)markers as promising biomarkers for cognitive frailty.
- 1 January 2019
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 177, 135-143
Antioxidants linked with physical, cognitive and psychological frailty: Analysis of candidate biomarkers and markers derived from the MARK-AGE study
- 1 January 2019
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 177, 135-143
Antioxidants linked with physical, cognitive and psychological frailty: Analysis of candidate biomarkers and markers derived from the MARK-AGE study
- Open Access
- 7 December 2016
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 22 (1) , 8-15
The Association Between BMI and Different Frailty Domains: A U-Shaped Curve?
- 7 December 2016
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 22 (1) , 8-15
Open AccessThe Association Between BMI and Different Frailty Domains: A U-Shaped Curve?